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Background: Growth factors are generally believed to have a perpetuating role in the development of diabetic
complications, However there is ample of evidence of a protective or therapeutic potential for some of them. IGF-I,
according to some reports, may contribute to complication development, although a protective role for IGF-I has
been claimed for all late diabetic complications, making it an exception among growth factors. Transforming
growth factor (TGF)-β1 as a pleiotropic cytokine is a key player in immunoregulation. Dysregulation of TGF-β1 in
diabetes has been addressed as a leading event of kidney pathologies, while there is no similar pivotal role for
TGF-β1 in diabetic retinopathy or neuropathy. An association study was conducted to evaluate the distinctive roles
of TGF-β1 and IGF-I in T1DM microvascular complications by gene variation-based regulatory mechanisms that are
operational in modulation of both in situ and systemic levels of the gene product.
Methods: Two polymorphisms of the IGF-I gene at positions −383*C/T and −1089*C/T and two functional TGF-β1
gene polymorphisms, including codons 10 (+869*C/T) and 25 (+915*G/C) were examined in 248 British Caucasian
T1DM patients and 113 healthy controls.
Results: The distribution of IGF-1 gene polymorphisms did not reflect any significant association with different
endpoints among the cases or different subgroups (complication triad) and controls. For TGF-β1 gene codon 25
polymorphism the low producer variant (allele C) were more frequent in cases than controls, which is compatible
with the anti-inflammatory role of TGF-β1 and for codon 10 polymorphism the frequency of allele C was highest
in retinopaths and, on the contrary and expectedly, nephropathy was more frequently accompanied by allele
T (high producer). The frequency of allele G (high producer) of codon 25 polymorphism was slightly higher in the
complication free group than in other subgroups.
Conclusion: Although there were some differences in distribution of allele and genotype frequencies of TGF-β1
gene polymorphism in diabetes microvascular complications the differences were not statistically significant.
Regarding IGF-1 our result firstly questions the functionality of the employed polymorphic marker and secondly
may entail that the main regulator of IGF-I functionality resides elsewhere rather than the IGF-I gene itself, such as
post-transcriptional regulation.
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Growth factors are generally implicated in the develop-
ment of diabetic retinopathy (DR) and diabetic nephrop-
athy (DN), while in diabetic neuropathy (DNU) some of
them (such as VEGF, IGF-I and NGF) have a protective
role. This differential impact of growth factors is partly
related to the discrete pathophysiological nature of these
different endpoints.
The IGF-I gene is located on the long arm of chromo-
some 12q22-24.1 [1,2]. The encoded IGF-1 protein is a
single chain polypeptide with 70 amino acids. Both IGF-
I and its specific receptor (IGF-IR) have strong structural
homology with pro-insulin and insulin receptor, respect-
ively. The main mode of action of IGF-I is endocrine
but, in contributing to the main pathways in the exacerba-
tion of diabetic complications, it could function in an auto-
(i.e. as an oncogene [3] or para-crine manner as well.
TGF-β1 is a homodimeric protein with a molecular
weight of about 25 KDa, encoded by a gene on chromo-
some 19q13 [4]. There are at least seven polymorphisms
in the TGF-β1 gene, but two of them have been identi-
fied as functional polymorphisms, which are associated
with interindividual variation in the level of its produc-
tion. These polymorphisms are located in the signal
sequence at position +869*C/T, which changes codon 10
(Leu→ Pro) and at position +915*G/C, which changes
codon 25 (Arg→ Pro) [5].
The pivotal role of TGF-β1 in development of DN
(mainly due to its hypertrophic and profibrotic effects) is
documented. The expression of TGF-β1 was shown to
be increased 3–10 fold in the glomeruli of STZ-diabetic
rats. Its elevation was both in local (glomerular) and cir-
culating form [6]. While the local (glomerular) increase
of TGF-β1 is attributable mainly to increased in situ
expression (TGF-β mRNA) [7,8], its systemic elevation
might be due to its release from platelets, which serve as
a large reservoir of TGF-β. Hyperfragility of platelets in
diabetes could lead to TGF-β1 release from platelets into
serum [9]. The exposure of endothelial cells to increased
serum TGF-β may in turn develop/precede generalised
basement membrane thickening.
TGF-β1 elevation has been reported as early as 24 h
following the onset of hyperglycaemia [10]. Similarly,
TGF-β protein immunostaining was elevated in the
kidneys of humans with diabetic nephropathy [11]. The
level of intraglomerular TGF-β1 mRNA has been corre-
lated with the staining intensity of collagen type IV in
the mesangium, glomerular basement membrane, and
Bowman’s capsule [8].
The elevation of all three TGF-β isoforms at the glom-
erular and tubolointerstitial levels along with increased
extracellular matrix synthesis has been documented in dif-
ferent glomerular diseases, including diabetic nephropathy
[12]. While the entire TGF-β axis is involved in diabeticnephropathy, TGF-β2 and TGF-β type II receptor have
displayed the most prominent changes at the protein level
in STZ-induced and BB-rats [13].
IGF-I serum levels usually have not been found increased
in diabetic patients. Instead, there is IGF-I depletion at the
systemic level, most profoundly in patients with poor gly-
caemic control [14]. At the tissue level, there is decreased
IGF-1 availability due to diminished serum IGF-I (free and
total) and elevated IGF-BP1 [15] (as an inhibitor of IGF-I)
[16]. As a result of improved metabolic control, the serum
level of IGF-I usually increases [17,18]. This may explain
the pathophysiology of the “bush fire” phenomenon, which
is transient aggravation of proliferative diabetic retinopathy
(PDR) following better glycaemic control [19].
The correlation of retinal ischemia with both local IGF-I
production (and also IGF-II and IGF-BPs) and angiogen-
esis [20] has been documented. However some studies
show serum IGF-I elevation [21], while other studies re-
veal no connection between serum IGF-I and DR [22],
some reports note its elevation at the later stage of DR
(too late to be considered a cause) and some cite only its
transient elevation just prior to DR commencement [23].
A considerable drop (30%) in levels of active TGF-β
has been observed in PDR. In massive ocular angiogen-
esis due to either diabetes or non-diabetic aetiologies,
the reduction of vitreous TGF-β was about ⅛ relative to
control levels [9].
Recently it has been reported that in type 2 diabetics
TGF-(1 gene polymorphism at codon 25 (+915*G/C)
is associated with PDR (vs type 2 diabetics without PDR,
p = 0.007), while the polymorphisms at positions –988C/
A, −800G/A, −509C/T, and at codon 10 (+869*T/C) were
not associated with PDR [24].
However, although active TGF-(1 is downregulated
in retinal angiogenesis due to ischemia, it seems TGF-
(1 down-regulation does not have a key role in diabetic
retinopathy.
In experimental animal models, it has been docu-
mented that intravitreal injection of IGF-I in rabbits [25]
and pigs [26] causes retinal neovascularisation and mi-
croangiopathy, correspondingly. Furthermore, suppres-
sion of serum IGF-I (secondary to GH down-regulation)
reduced the progression of retinal neovascularisation
in a mouse model of retinal ischemia [27]. The vitreous
level of IGF-I in proliferative DR was 2.5 fold higher than
controls [28];
Intravitreal IGF-I was significantly higher in diabetics
than in controls, and the highest intravitreal level was
found in insulin-treated patients with actively vascu-
larised retinal membrane. Interestingly, among different
growth factors (IGF-I, bFGF and TGF-β2), only IGF-I
had a constantly higher vitreal level in all diabetic patients
with proliferative DR (with regard to diabetes type or
method of glycaemic control, and neovascular activity),
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instance, bFGF was higher in non-insulin treated patients
and TGF-β2 was higher among those treated with insulin,
but IGF-I was increased in both populations [29];
In terms of potential causes of elevated IGF-I in DR,
excess secretion or release from the retina by active
neovascularised membranes, contribution from systemic
sources, and impaired degradation of IGF-I (IGF-BPs ac-
tion) have been mentioned [29].
A considerable drop (30%) in levels of active TGF-β
has been observed in PDR. In massive ocular angiogen-
esis due to either diabetes or non-diabetic aetiologies,
the reduction of vitreous TGF-β was about ⅛ relative to
control levels [9]. On the other hand, as the vitreous
extract of normal individual inhibits retinal capillary
growth in vitro [30], such an inhibitory property was as-
cribed to secretions of pericytes and smooth muscle cells
[31]. However, if TGF-(is acting in a paracrine manner,
its vitreous level may not reflect the local concentration.
Seemingly pericytes could regulate endothelial cell
proliferation by secretion of TGF-(, and subsequently by
its conversion from latent to active TGF-(. In co-culture
with pericytes and smooth muscle cells, the migration of
endothelial cells was inhibited by activation of a latent
TGF-(−like molecule [32] and likewise co-culture with
pericytes resulted in therelease of active TGF-(, which
is a likely inhibitor of angiogenesis by endothelial cells in
the eye [33]. These observations are consistent with peri-
cyte loss as a prodromal event in endothelial cell prolifera-
tion in DR.
Recently it has been reported that in type 2 diabetics
TGF-(1 gene polymorphism at codon 25 (+915*G/C)
is associated with PDR (vs type 2 diabetics without
PDR, p = 0.007), while the polymorphisms at positions –
988C/A, −800G/A, −509C/T, and at codon 10 (+869*T/C)
were not associated with PDR [24].
However, although active TGF-(1 is downregulated in
retinal angiogenesis due to ischemia, it seems TGF-
(1 down-regulation does not have a key role in dia-
betic retinopathy.
With regard to diabetic neuropathy IGF-I decrease
growth factor synthesis by target organs, disrupt retro-
grade transport of growth factors to the neuronal cell
body, effect of signal transduction mechanisms of growth
factors in neurons, alteration of the ability of neurons or
Schwann cells to produce growth factors required for nor-
mal cell maintenance [34]. a) IGF-I (and IGF-II) mRNA
was significantly decreased in peripheral nerves, early after
development of diabetes in rats in comparison to non-
diabetic rats.
It has been supposed that IGF-I (and IGF-II) has a
neurotrophic effect and promotes nerve regeneration as
well. The rate of nerve regeneration is reduced by anti-
bodies to both IGF-I and IGF-II [35]. Neurite (axon anddendrite) sprouting in muscle is intensified by IGF-I and
IGF-II [36]. A significant decrease in systemic IGF-I
(together with elevated IGFBP-1) has been reported in
patients with severe neuropathic complications [37]. How-
ever, it is not known that how IGFs could provoke nerve
regeneration.
NGF, IGF-I and ciliary neurotrophic factor (CNTF) are
crucial players in the normal growth, maintenance and
regeneration of the peripheral nervous system, but there
is no such role for TGF-(1 in diabetic neuropathy. How-
ever, the lack of TGF-(1 up-regulation has been pro-
posed as the reason for impaired healing in diabetic foot
ulcers [38].
Given that IGF-I and TGF-β1 have established role in
the diabetic complication triad, we sought to determine
whether their genetic variations encode the genetic pre-
disposition to diabetic complications. Two polymorphisms
of the IGF-I gene at positions −383*C/T and −1089*C/T
were used as markers in a candidate gene association
study. Also the association of two SNPs of TGF-β1 gene
at positions +869*T/C and +915*G/C with susceptibility
to T1DM and the development of late complications of
diabetes was examined.
Patients and controls
As an out-patient clinic in the North West region of
the UK, about 5000 T1DM registered patients are
regularly attending to the Manchester Diabetes Centre.
In the present cross-sectional study, in total 248 unrelated
British Caucasian attendees with T1DM were randomly
selected during 1999–2002 as the patient group. The eth-
ical approval was obtained from the Manchester Royal
Infirmary. Written informed consent was obtained from
all patients attending the study.
All patients fulfilled the relevant criteria for related
diagnosis as are detailed later. To be on the safe side, pa-
tients who had diabetes less than 3 years were excluded
from analysis.
Type 1 diabetes
Diabetes was diagnosed according to the criteria, which
was suggested by an expert committee in 1997 (report of
the expert committee on the diagnosis and classification of
diabetes Mellitus, [39]). The diabetic patients included in
the present study fulfilled at least one of the triple criteria
recommended by the expert committee, detailed as follows:
a) Symptoms of hyperglycaemia (polyuria, polydipisia,
unexplained weight loss) plus random plasma glucose >
200 mg/dL (11.1 mmol/L). Random is defined as any
time of day without regard to time since last meal.
b) Fasting plasma glucose (FPG) > 126 mg/dl
(7.0 mmol/L). Fasting is defined as no caloric intake
for at least 8 hours.
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(11.1 mmol/L) during an oral glucose tolerance test
(OGTT). The test should be performed as described
by the World Health Organization (WHO), using a
glucose load containing the equivalent of 75-g
anhydrous glucose dissolved in water.
Diabetes was regarded as T1DM if it was diagnosed
before age of 30 years and accompanied with acute onset
and treatment with insulin began within the first year of
diagnosis and continued thereafter.
Diabetic retinopathy (DR)
The back of the eye was examined by fundoscopy (after
pupillary dilatation) and when more than five dots or
blots per eye, hard or soft exudates or new vessels were
evident the diagnosis of retinopathy was applied. Pa-
tients who had a history of laser treatment were also
diagnosed as retinopathy.
Diabetic nephropathy (DN)
The elevation of AER (> 300 mg-2 g/day) at least on two
of three occasions and/or 3 positive Albustix over the past
12 months were evident to mark patients as nephropath,
while a urinary tract infection (UTI) was ruled out already.
Diabetic neuropathy (DNU)
Neurothesiometer -a clinical electromagnetic vibrating
device- was applied for screening of peripheral dia-
betic neuropathy, which quantifies the vibration sensi-
tivity through the measurement of vibratory perception
threshold (VPT), while the patient’s eye is closed and the
probe of neurothesiometer is placed on the hallux of
the toe. An average of 3 readings were taken. DNU was
diagnosed when VPT was more than 25 volts (vibration
threshold above 25 volts indicates a high risk of ulcer-
ation). The symptoms of sensory and/or motor neuropathy
were looked for, like parasthesia, numbness, tingling, noc-
turnal rest ache, all in the absence of peripheral vascular
disease as non-specific (non-diabetic) underlying cause.
The excluding of peripheral vascular disease was approved
by palpable pulses and measuring of ankle brachial pres-
sure index.
Materials and methods
ARMS-PCR was carried out to genotype healthy con-
trols and patients for TGF-β1 gene polymorphisms at
codons 10 (+869*T/C) and 25 (+915*G/C) using as pre-
viously described [40]. Also the ARMS-PCR method
was developed for genotyping of IGF-I (−383*C/T
and −1089*C/T) polymorphisms ([41]; unpublished data).
A non-polymorphic fragment (425 bp in length) of the
human growth hormone (HGH) gene also was chosen
as a target for internal control primers (Table 1).A master mix solution was used for DNA amplifica-
tion. This master mix includes 22% of Ready Load Reac-
tion Buffer (AB Technology, UK), 22% of 200 μM
dNTPs (AB Technology, UK), 13% of 1.5 mM magne-
sium chloride (AB Technology, UK), 31% of 60% (W/V)
sucrose, 11% internal control primer (1 μM each), and
1.1% of Thermoprime DNA Polymerase (AB Technol-
ogy, UK). For each sample, 1.5 μl of DNA was added to
15 μl of the master mix solution and then 5 μl of specific
primer mix was aliquoted to 5 μl of master mix solution,
which already contains DNA as well. After that, this
10 μl reaction was amplified on a PTC-100 PCR thermal
cycler (MJ Research, Inc), where the cycles was pro-
grammed as follows: 1 minute at 96°C followed by 10 cy-
cles of 15 seconds at 95°C, 50 seconds at 65°C, 40 seconds
at 72°C followed by 20 cycles of 20 seconds at 95°C, 50 sec-
onds at 59°C and 50 seconds at 72°C.
In gel electrophoresis, according to the presence or ab-
sence of amplified targeted sequence, the type of alleles
(genotype) are identified. The amplified products were
visualized in a 2% agarose gel against 200 bp ladders and
stained with 5 μl (0.5 mg/ml) of ethidium bromide.Statistical analysis
Strength of association between different groups and
alleles or genotypes of polymorphisms were estimated
using odds ratios (OR) and 95% confidence intervals
(CI). Levels of significance were determined using contin-
gency tables by either Chi-square or Fisher exact analysis
using the STATA (v8) software (STATA Software, College
Station, Texas, USA).Results
Figure 1 describes the association between age at onset
of diabetes and development of complications in our pa-
tients. Among triad of diabetic complications only in DR
the impact of age at the onset was statistically determinant
(p = 0.0008) for the development of complications. The
impact of the age at the onset was insignificant for the
development of both DN (p = 0.2) and DNU (p = 0.7).
The male/female ratio was 113/89 and mean age of
patients was 41.8 ± 13.1 and mean duration of diabetes
was 18.3 ± 11.7 while mean duration of diabetes among
complication free patients was 10.9 ± 7.8.
The distribution of IGF-I gene polymorphisms at
positions −383*C/T and −1089*C/T were examined by
ARMS-PCR in 248 diabetic subjects and 113 healthy
controls (Tables 2 and 3). The distribution of these poly-
morphisms did not associate with any significant differ-
ences among cases (group/subgroups) and controls.
The distributions of TGF-β1 gene polymorphisms
were evaluated in 248 diabetic subjects and 119 healthy
controls. The distribution of these polymorphisms was
Table 1 The primers sequences for genotyping of IGF-1 and TGF–β1 polymorphisms
Internal control primers (Human Growth Hormone) PCR product size
HGH1 5′- GCCTTCCCAACCATTCCCTTA-3′ 425 bp
HGH2 5′- CAAGGATTTCTGTTGTGTTTC-3′
Gene specific primers
IGF-I (−383*C/T) 5′-GTGACAGGCAGCCTAGTAGA-3′ 189 bp
5′-TCCCAGTTGCCAAGTGAGG-3′
5′-GTCCCAGTTGCCAAGTGAGA-3′
IGF-I (−1089*C/T) 5′-CACTTGCCTTTGCCATTGAG-3′ 244 bp
5′-AGTCCCCTGAGAGTCATGC-3′
5′-CAGTCCCCTGAGAGTCATGT-3′
TGF–β1 (Codon 10) 5′- TCCGTGGGATACTGAGACAC- 3′ 241 bp
5′- GCAGCGGTAGCAGCAGCG-3′
5′- AGCAGCGGTAGCAGCAGCA-3′
TGF–β1 (Codon 25) 5′- GGCTCCGGTTCTGCACTC-3′ 233 bp
5′- GTGCTGACGCCTGGCCG-3′
5′- GTGCTGACGCCTGGCCC-3′
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controls (Tables 4 and 5).
Discussions
In present study there was no significant association in
either TGF-β1 allele or genotype frequency across the dif-
ferent groups/subgroups with multiple comparisons, but
comparatively there were some points for consideration.
In polymorphism at codon 10*C/T the frequency of
allele C (low producer variant) was constantly increased
among patients, while a meaningful variation of its fre-
quency was also evident among different subgroups. The







Age at the onset > 15
(N) 66 85
Age at the onset < 15
(N) 34 15
%
Figure 1 The comparative illustration of triad of microvascular diabet
(under or over 15 years).subgroups can be explained by the immunoregulatory or
anti-inflammatory function of TGF-β1, that is probably
attenuated in allele C carriers. The highest frequency of
allele C was found in diabetic subjects without the triad
of complications (complication free group), but it was
not meaningful as, for instance, patients with DR were
frequently the carrier of allele C, too.
Among different complications, the highest frequency
of allele C was present in subjects with DR, which may
feebly suggest again that low level of TGF-β1 is favored
in DR. Among cases the highest frequency of allele T
(high producer variant) was present in the subgroup of
diabetic nephropathy, which can be explained by the3 4 5 6 7 8
69 77 76 74
31 23 24 26
ic complications according to the age at the onset of diabetes
Table 2 Distribution of genotype and allele frequencies of the IGF-I −383*C/T polymorphism in healthy controls (C),
T1DM subjects (P), diabetic retinopaths (DR), nephropaths (DN), neuropaths (DNU) and complication free (CF) group*
IGF-I −383*C/T C n (%) P n (%) DR n (%) DN n (%) DNU n (%) CF n (%)
Genotype
CC 89 (91.0) 223 (90.0) 121 (89.6) 78 (90.7) 78 (95.0) 90 (92.0)
CT 8 (8.0) 23 (9.2) 12 (8.9) 7 (8.1) 4 (5.0) 7 (7.0)
TT 1 (1.0) 2 (0.8) 2 (1.5) 1 (1.2) 0 (0.0) 1 (1.0)
Allele
C 186 (95.0) 469 (94.6) 254 (94.0) 163 (94.8) 160 (95.0) 187 (95.4)
T 10 (5.0) 27 (5.4) 16 (6.0) 9 (5.2) 4 (5.0) 9 (4.6)
*No significant difference was evident between any groups/subgroups.
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but it was still lower than healthy controls, which is ex-
plicable by the pre-selection of allele C by the preceding
disease (diabetes). However, when diabetic subjects were
compared with each other according to presence or ab-
sence of DN, the allele distribution showed no signifi-
cant difference (p = 0.47).
With respect to the polymorphism at codon 25 (+915*G/
C), there was no significant association between the
polymorphic alleles/genotypes with different groups and
sub-groups, as well. In accordance with TGF-β1 codon 10
polymorphism, the low producer variant (allele C) was
more frequent in cases than controls, which is compatible
with the anti-inflammatory role of TGF-β1. With regard
to the frequency of allele G (high producer variant), while
the patients as a whole and also patients with different
complications reflected a lower frequency of this allele,
the complication free subgroup possessed a higher fre-
quency than controls. While this feature is explainable
by a protective role of the high producer allele (G)
against development of diabetic complications, it con-
trasts with the distribution of codon 10 variants, where
the low producer variant (allele C) frequency was highest
in the complication free group. Nevertheless, this conflict-
ing substantiation may question seriously the soundness
of dividing criteria applied for patients’ stratification, as it
was based on negative findings (absense of complications)Table 3 Distribution of genotype and allele frequencies of th
T1DM subjects (P), diabetic retinopaths (DR), nephropaths (D
IGF-I −1089*C/T C n (%) P n (%) DR
Genotype
CC 8 (7.0) 13 (5.0) 6
CT 50 (44.3) 99 (40.0) 49
TT 55 (48.7) 136 (55.0) 80
Allele
C 66 (29.0) 125 (25.0) 61
T 160 (71.0) 371 (75.0) 209
*No significant difference was evident between any groups/subgroups.rather than positive findings to label the complication free
patients as a homogeneous group.
The highest frequency of allele C (the low producer
variant) was evident in subjects with diabetic retinopathy
that is compatible with functional property of TGF-β1 as
an anti-proliferative mediator. It is also consistent with
the data of TGF-β1 codon 10 polymorphism in DR.
However, since the main intent for analysis of TGF-β1
gene polymorphism in the present study was to explore
its impact on development of DN, it was expected to ob-
serve an increase in frequency of high producer variants
(allele T and G, relative to polymorphisms at codon 10
and 25, respectively) in DN. Though a number of studies
corroborated that expectation, but it was not evident in
this study. As among the triad of diabetic complications,
only DN can lead to death (since kidney is a vital organ),
non-association findings may be false, secondary to the
“survivor” (selective survival) effect. It entails that in
cross sectional studies, like the present study, some frac-
tion of the risky genotypes (associated with mortal traits)
are previously excluded from the study population by
death, and subsequent under-representation of such
risky genotypes among cases could potentially lead to a
false negative association.
In accordance with our data similar negative results
have been reported in advanced diabetic nephropathy,
while a higher number of alleles (3 in coding regione IGF-I −1089*C/T polymorphism in healthy controls (C),
N), neuropaths (DNU) and complication free (CF) group*
n (%) DN n (%) DNU n (%) CF n (%)
(4.4) 5 (5.8) 4 (4.9) 4 (4.0)
(36.3) 34 (39.5) 35 (42.7) 40 (41.0)
(59.3) 47 (54.7) 43 (52.4) 54 (55.0)
(22.6) 44 (25.6) 43 (26.2) 48 (24.5)
(77.4) 128 (74.4) 121 (73.8) 148 (75.5)
Table 4 Distribution of genotype and allele frequencies of the TGF-β1 at codon 10*C/T polymorphism in healthy
controls (C), T1DM subjects (P), diabetic retinopaths (DR), nephropaths (DN), neuropaths (DNU) and complication
free (CF) group*
TGF-β1 codon 10*C/T C n (%) P n (%) DR n (%) DN n (%) DNU n (%) CF n (%)
Genotype
CC 15 (12.5) 39 (15.7) 23 (17) 12 (14) 13 (15.85) 19 (19.39)
CT 57 (48.0) 126 (50.8) 69 (51.1) 43 (50) 40 (48.78) 47 (47.96)
TT 47 (39.5) 83 (33.5) 43 (31.9) 31 (36) 29 (35.37) 32 (32.65)
Allele
C 87 (36.5) 204 (41.1) 115 (42.6) 67 (39) 66 (40.24) 85 (43.37)
T 151 (63.5) 292 (58.9) 155 (57.4) 105 (61) 98 (59.76) 111 (56.63)
*No significant difference was evident between any groups/subgroups.
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ined [42].
Since the local expression/activation of TGF-β1 would
contribute to the proliferative phase of DR, the increased
frequency of high producer variants of TGF-β1 in this
study also are explicable and expected in DR, as has
been documented recently [24].
The “no association” result between TGF-β1 gene
polymorphisms and total IDDM group may imply that
the proposed role of TGF-β1 in the induction and devel-
opment of IDDM might be distal and non-decisive, for
example, in comparison to other candidate cytokines,
like TNF-α or IFN-γ.
Given the tissue damage that occurs frequently in dia-
betes [43], an elevation of IGF-I is increasingly required
[43], in contrast IGF-I levels are progressively decreasing
in diabetes, preceding the formation of late complica-
tions. Consequently, at the tissue level, particularly in
the kidneys, eyes and neurons, there is a deprivation of
IGF-I. This rationale also is supported by previous find-
ings documenting a protecting role for IGF-I in DNU
due to its tissue regenerating [37] and anti-apoptotic (in
glucose-induced apoptosis) properties [44]. Ishii in 1986–
1987 had presented the same speculation with regard to
the significant suppressive role of IGF-I and II in DNU
(reviewed in [34]). The “IGF-I deficiency” theory can beTable 5 Distribution of genotype and allele frequencies of th
trols (C), T1DM subjects (P), diabetic retinopaths (DR), nephro
group*
TGF-β1 codon 25* G/C C n (%) P n (%) D
Genotype
GG 97 (81.5) 201 (81)
GC 21 (17.6) 44 (17.8)
CC 1 (0.9) 3 (1.2)
Allele
G 215 (90.3) 446 (90) 2
C 23 (9.7) 50 (10)
*No significant difference was evident between any groups/subgroups.viewed as an upgrade of the “GH hyper-secretion” hypoth-
esis [45], reducing the emphasis on the role of GH, and
acknowledging that the GH-IGF axis is deranged in
diabetes.
In contrast to such strong evidence and facts implying
a decisive role for IGF-I in diabetic complications, we
found no association between IGF-I gene polymor-
phisms and the development of T1DM or its late micro-
angiopathic complications. Such non-association results
cannot necessarily rule out or discount the involvement
of IGF-I in the development of either diabetes or late
complications. It can only suggest that the pair of IGF-I
polymorphisms (but not other potential polymorphisms
and more notably the IGF-I gene/molecule itself ) do not
influence the development of those pathologies in the
studied population.
With regard to remarkable alteration of IGF-I levels
particularly in diabetic complications (detailed above) it
strongly suggests other regulatory mechanisms i.e. post
transcriptional rather than gene polymorphism based,
may be involved. Even more, by the same concentration/
expression different impact/outcome can result from
IGF-I through the modulating role of IGF-I binding pro-
teins and IGF-I receptors.
It also can be envisaged that due to the essential role of
IGF-I in physiological homeostasis, mainly via its metabolice TGF-β1 at codon 25*G/C polymorphism in healthy con-
paths (DN), neuropaths (DNU) and complication free (CF)
R n (%) DN n (%) DNU n (%) CF n (%)
104 (77) 68 (79) 65 (79.3) 83 (84.7)
28 (20.8) 17 (19.8) 16 (19.5) 15 (15.3)
3 (2.2) 1 (1.2) 1 (1.2) 0 (0.00)
36 (87.4) 153 (89) 146 (89) 181 (92.3)
34 (12.6) 19 (11) 18 (11) 15 (7.7)
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(similar to house keeping genes products) is not deter-
mined by a quantative (rheostat-like) switching mechan-
ism and thus does not accommodate quantative changes
at the transcriptional level (i.e. due to the impact of any
polymorphism) but instead it may comply with on/off bin-
ary switches, transcription rate being constant during the
“on” phase [46].
In terms of the statistical view, some points can be
underlined. Firstly, when the frequency of a variant allele
is very low (as the allele T of the −383*C/T polymorph-
ism), it generally weakens the power of that polymorph-
ism as a marker. Such low frequency can be due to its
non-functionality implying that it has been unaffected by
and excluded from selective forces and thus cannot be
accounted for as a phenotype modifier and therefore an
efficient genetic marker.
However, if that polymorphism is functional, both
advantageous and disadvantageous effects are feasibly
explicable in different ways. If it is advantageous it might
be a newly arisen mutation that has not had enough
time to spread across population and be more frequent
secondary to selective forces. If it is disadvantageous, the
allele may be in the process of extinction. Therefore, it is
too late now to evaluate its effects while it is near to en-
tire elimination. In both these circumstances, even when
it is functional, that polymorphism again is not a reliable
marker since it was not actually present (too early/too
late exposure) in the majority of the study population
(both cases and patients) to affect the progression of
diabetic complications.
One of the main limitations in our study was small
sample size. Low frequency polymorphic alleles, even in
the case of their relevance and connection with the dis-
ease, require a massive number of cases and controls to
identify reliably its impact on the disease. For example,
with the number of patients with different complications
and of controls in the present study in the case of IGF-I −
383*C/T to achieve significance at the 0.05 level, power
calculations show it is only possible to discover its impact
if a very significant relative risk is expected.
However, the role of IGF-I in the development of
diabetic complications is almost certain and our findings
only indicate that that influence of IGF-I might not be
dictated by the examined SNPs. If other variations of
IGF-I is detected, the next step is to pursue the task of
this study by using them as new gene markers.
Conclusion
In summary, the discrepancies of finding in this study
compared to previous studies may reflect the dynamic
nature and diverse outcome of biological phenomenon
that are regulated by different mechanisms at different
levels.These results may lead us erroneously to consider a
deterministic link between genotypes and phenotypes in
complex traits.
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